Rpharmy Memorial
Approved Hospital Formulary
Formulary Addition Requisition (Position 1)
Demo Page
Rpharmy Memorial Formweb Change Request (Position 2)
Search by name
Search by class
Show Therapeutic Classes
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Black Box Warning
Biosimilar Preference List
Do Not Crush
High Cost Drugs
LASA
Non-Formulary
Therapeutic Interchange
REMS
Renal Dosing
Restricted
Questions & Suggestions (Position 3)
Hazardous Drugs
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
News
Rpharmy Memorial
Approved Hospital Formulary
Formulary Addition Requisition (Position 1)
Demo Page
Rpharmy Memorial Formweb Change Request (Position 2)
Search by name
Additional search options
Search by class
Show Therapeutic Classes
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Black Box Warning
Biosimilar Preference List
Do Not Crush
High Cost Drugs
LASA
Non-Formulary
Therapeutic Interchange
REMS
Renal Dosing
Restricted
Questions & Suggestions (Position 3)
Hazardous Drugs
Search results for:
ado-trastuzumab emtansine
ado-trastuzumab emtansine
Drug Name
Form
Strength
Non-Formulary
Restricted
Renal Dosing
REMS
Therapeutic Interchange
Notes
Kadcyla
POWDER FOR INJECTION, INTRAVENOUS
100 mg; 160 mg
Last updated:
Apr. 27, 2026
ado-trastuzumab emtansine
Black Box Warning:
Hepatotoxicity, Cardiac Toxicity, Embryo-Fetal Toxicity
Restricted:
This medication is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (ie Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader.
UpToDate
Recent Citations via Medline (PubMed)
FDA Daily Med Package Inserts
FDA Approved Drug Products
Drugs.com/Pill Identifier